Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: Usefulness of MS functional composite and Expanded Disability Status Scale

European Journal of Neurology

Volumn 15, Issue 3, 2008, Pages 284-288

  Pascual, A M ^a   Bosca I ^a   Coret, F ^b   Escutia, M ^a   Bernat, A ^b   Casanova, B ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Acute treatment; Expanded Disability Status Scale; Multiple sclerosis; Multiple sclerosis functional composite; Oral methylprednisolone; Relapse

Indexed keywords

ASCORBIC ACID; ASPARTIC ACID; BETA1A INTERFERON; BOI K ASPARTICO; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; OMEPRAZOLE; SOLU MODERIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CORRELATION ANALYSIS; DRUG MEGADOSE; DRUG SAFETY; EVALUATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GASTRIC INTOLERANCE; HEART PALPITATION; HUMAN; INSOMNIA; LEG EDEMA; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPROTECTIVE AGENTS; SEVERITY OF ILLNESS INDEX;

EID: 39149100974     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02061.x     Document Type: Article

References (18)

1. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Annals of Neurology 1997 42 : 379 382.
2. Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study. Multiple Sclerosis 2006 12 : 180 186.
3. Cohen JA, Cutter GR, Fischer JS, et al. IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002 59 : 679 687.
4. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003 126 : 770 782.
5. Ozakbas S, Cagiran I, Ormeci B, Idiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. Journal of the Neurological Sciences 2004 218 : 3 7.
6. Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurologica Scandinavica 2002 105 : 164 168.
7. Barnes MP, Bateman DE, Cleland PG, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. Journal of Neurology, Neurosurgery and Psychiatry 1985 48 : 157 159.
8. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. Journal of Neurology, Neurosurgery and Psychiatry 1987 50 : 511 516.
9. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989 39 : 969 971.
10. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. Journal of Neurology, Neurosurgery and Psychiatry 1993 56 : 1219 1220.
11. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997 349 : 902 906.
12. Sellebjerg F, Frederiksen JL, Nielsen HS, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998 51 : 529 534.
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983 13 : 227 231.
14. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001 50 : 121 127.
15. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Multiple Sclerosis 1999 5 : 244 250.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983 33 : 1444 1452.
17. Ozakbas S, Ormeci B, Idiman E. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies. Journal of the Neurological Sciences 2005 232 : 65 69.
18. Uttner I, Müller S, Zinser C, et al. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Neurology 2005 64 : 1971 1973.